The future of pancreatic cancer care

Pancreatic cancer survival rates have doubled in the last few years from 5 to 10 percent. This is thanks largely to clinical trials that have led to better treatments and a better understanding of how to tailor them to the individual. Despite the advancements, pancreatic cancer remains difficult to treat and long-term survival remains low. But, experts are hopeful that cutting-edge technology such as organoids — a collection of a patient’s cells that are maintained in a petri dish — will lead to continued improvements in outcomes.

Featured speakers: Matthew Weiss, MD, physician-in-chief and director of surgical oncology for the Northwell Cancer Institute; and Sepideh Gholami, MD, F.A.C.S., cancer specialist and surgeon at UC-Davis in California.